The "Bench-to-Bedside" nature of our research allows us to investigate the genetic and immunological pathways involved in the development and progression of Squamous Cell and Basal Cell Carcinomas obtained directly from patients suffering from such skin cancers. Our diverse team of Physicians, Scientists, Medical fellows and Biomedical Engineers has driven the development and application of technology to improve our ability to diagnose and treat skin cancers.
RECENT PUBLICATIONS & ABSTRACTS:
- Interleukin-22 and Cyclosporine in Aggressive Cutaneous Squamous Cell Carcinoma, Dermatologic clinics. 2017:35(1):73-84
- MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma is Associated with Advanced Tumor Stage and Poor Prognosis. Journal of Investigative Dermatology 2016
- Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22. JCI Insight 2016
- Defining gene expression profiles for subtypes of high risk squamous cell carcinoma [SCC] using RNA from formalin fixed paraffin embedded specimens [FFPEs] [Meeting Abstract #152] Journal of investigative dermatology 2016
Our team presented five abstracts and posters at the Society of Investigative Dermatology in May of 2016. Click below to learn more about our recent awards, conferences and publications.
